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Background: Human malaria infections caused by the parasite Plasmodium falciparum often contain more than
one genetically distinct parasite. Despite this fact, nearly all studies of multiple strain P. falciparum infections have
been limited to determining relative densities of each parasite within an infection. In light of this, new methods are
needed that can quantify the absolute number of parasites within a single infection.
Methods: A quantitative PCR (qPCR) method was developed to track the dynamic interaction of P. falciparum
infections containing genetically distinct parasite clones in cultured red blood cells. Allele-specific primers were
used to generate a standard curve and to quantify the absolute concentration of parasite DNA within multi-clonal
infections. Effects on dynamic growth relationships between parasites under drug pressure were examined by
treating mixed cultures of drug sensitive and drug resistant parasites with the anti-malarial drug chloroquine at
different dosing schedules.
Results: An absolute quantification method was developed to monitor the dynamics of P. falciparum cultures
in vitro. This method allowed for the observation of competitive suppression, the reduction of parasites numbers
due to the presence of another parasite, and competitive release, the improved performance of a parasite after the
removal of a competitor. These studies demonstrated that the presence of two parasites led to the reduction in
density of at least one parasite. The introduction of drug to a mixed culture containing both a drug resistant and
drug sensitive parasites resulted in an increased proportion of the drug resistant parasite. Moreover, following drug
treatment, the resistant parasite experienced competitive release by exhibiting a fitness benefit greater than simply
surviving drug treatment, due to the removal of competitive suppression by the sensitive parasite.
Conclusions: The newly developed assay allowed for the examination of the dynamics of two distinct clones
in vitro; both competitive suppression and release were observed. A deeper understanding of the dynamic growth
responses of multiple strain P. falciparum infections, with and without drug pressure, can improve the
understanding of the role of parasite interactions in the spread of drug resistant parasites, perhaps suggesting
different treatment strategies.Background
Natural parasitic infections are often diverse, containing
multiple parasite species and/or distinct genotypes of
the same species [1]. Parasites of the Plasmodium genus,
the cause of human malaria, are no exception as infec-
tions of multiple strains or species of parasites have been
widely reported [2-7] and may be typical in high trans-
mission regions [7,8]. Growth relationships between
parasite types within a single host have significant* Correspondence: mferdig@nd.edu
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reproduction in any medium, provided the orevolutionary implications for selection of fitness and
drug resistance traits that can greatly impact public
health [9]. However, surprisingly little is known about
the dynamics of multi-clone infections and previous
investigations have been limited to the determination of
relative amounts of parasites within multi-clonal infec-
tions. While relative quantification is informative in de-
termining which parasite is present in greater numbers,
the reliance on relative abundance limits the insight that
can be gained into the dynamics of parasite growth. For
example, relative density measurements do not clarify
whether the minority parasite population is expanding,
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parasite; i.e., a parasite that is competitively suppressed
will have not only a lower density than the majority
parasite but also a lower density than when grown in
single culture. Recently, it has been proposed that
within-host ecology can be harnessed in control efforts
to stop the spread of drug resistant parasites [9], empha-
sizing the need for tools and experimental approaches to
explore within-host dynamics of Plasmodium falciparum
infections.
Diversity within P. falciparum infections is an area of
expanding interest. Genotyping highly variable genes,
such as merozoite surface protein 1 (msp1), merozoite
surface protein 2 (msp2) and glutamine rich protein
(glurp), is the most common method of identifying indi-
vidual clones within an infection [7]. Other studies used
microsatellites (MS) [10] and multiplexed real time PCR
[11]. More recently, the complexity of infection has also
been investigated with massively parallel pyrosequencing
on the 454 sequencing platform, which has the distinct
advantage of being able to sequence single strands of
DNA; consequently, parasite variants that make up only
a small proportion of the overall infection population
can be detected. Deep sequencing revealed an even
greater complexity of infection, with average of 5.0 more
variants identified than using nested PCR based methods
utilized by earlier studies [7]. In addition, this study
showed an expansion of specific msp2 genotypes after
drug treatment, however, the assay is not able to directly
link these genotypes to drug resistance [7]. High
throughput sequencing has also been used to calculate
multiplicity of infection on small amounts of blood
taken directly from patients [12].
Most reports of multiple infections of human malaria
have relied on relative quantification methods; however,
methods that determine the absolute amount of each
parasite strain within an infection have been developed
for the rodent malaria model Plasmodium chabaudi [13-
15]. These studies revealed that the presence of two
parasite clones led to the reduction in density of at least
one clone, a phenotype termed competitive suppression
[16]. Additionally, the introduction of drug pressure to a
mixed culture containing drug resistant and drug sensi-
tive parasites resulted in a greater transmission potential
of the drug resistant parasite. Another effect of drug
treatment is that the resistant parasite experiences com-
petitive release. In this case, the resistant parasite exhi-
bits a fitness benefit greater than simply surviving drug
treatment, as it actually expands to fill the niche previ-
ously inhabited by the sensitive parasite, due to the re-
moval of competitive suppression by the sensitive
parasite. The degree of release is dependent both on the
timing of drug treatment and the dose given [17,18].
More alarmingly, when a mixed infection containingboth sensitive and resistant parasites was treated with
drug, the resistant parasite reached a greater density
than if it were growing in a host alone, a phenomenon
termed treatment-induced facilitation which has also be
observed in humans [6,14,17]. The development of simi-
lar quantitative methods for P. falciparum will enhance
efforts to understand the outcomes of multi-clonal infec-
tions. These in vitro assays allow for control of some of
the many variables influencing competitive interactions
that cannot be controlled in the host.
Methods
Parasite culture
Parasites used for this study include the CQS parasite
clone, HB3, and CQR clones, Dd2 and 7C424. HB3 ori-
ginated in Central America and is sensitive to most anti-
malarial drugs except for low-level resistance to pyri-
methamine and sulfadoxine. Dd2 is a multidrug resistant
parasite originating from Southeast Asia, with high levels
of resistance to all anti-malarial drugs except the 8-ami-
noquinolines. 7C424 is a CQR progeny of the HB3×Dd2
cross. Parasites were grown in complete media (CM)
[370uM hypoxanthine (Hx) (Sigma), and 25 mM HEPES
(Sigma); 0.5% Albumax II (Gibco), 10ug/mL gentamycin
(Gibco), and 0.225% sodium bicarbonate (Biosource) in
RPMI-1640 medium (Gibco)] at approximately 5%
hematocrit (hct) in O+ RBC. Cultures were maintained
at a constant pH, 7.0-7.5, temperature, 37°C, and atmos-
phere, 5% CO2/5% O2/90%N2 with daily media changes.
Competition assays
To quantify the dynamics of a multiple infection of Dd2
and HB3 in vitro, a qPCR assay was developed using
known sequence polymorphisms in the merozoite sur-
face protein 1 (msp1) gene. Parasites were synchronized
using 5% D-sorbital and assays were initiated 48 hours
later. Assays were initiated at 0.25% parasitaemia and 5%
haematocrit for single cultures. Mixed cultures were
initiated in triplicate at 0.25% parasitaemia of each para-
site (total parasitaemia of 0.5%) and 5% haematocrit. Five
mL cultures were maintained in triplicate for five full
cell cycles. Media was changed daily and a 300 uL sam-
ple was retained and stored at −20°C. DNA was
extracted from samples using an E.Z.N.A. kit (Omega
biotech) following manufacturer’s instructions. To deter-
mine the outcome of the assay t-test were performed on
the data from the last day of the experiment. Assays
were stopped on day 11, near the point at which the cul-
ture system could not support the general healthy ex-
pansion due to high parasitaemia.
For drug treated competition assays parasites were cul-
tured for 72 hours to establish an infection before con-
stant CQ (50 nM) was initiated and maintained for the
duration of the assay. Fifty nM CQ was chosen because
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IC50 = 27.4nM) for HB3, but does not significantly affect
CQR parasite 7C424 (approximately the IC10, IC50 =
327.5nM) [19]. Application of drug treatment was
delayed to mimic conditions in a mouse model where
competitive release was observed when drug treatment
was initiated after an infection had been established [17].
Cultures for the drug treated assays and controls were
initiated as described above; 50 nM CQ was added to
the media and this concentration was maintained for the
duration of the assay. Three treatments were used for
drug treated assays: (1) a no-drug control identical to
the previous no drug assay; (2) CQ drug treated on day
3 for mixed and single culture controls; and (3) CQ drug
treated on day 5 for both mixed and single culture con-
trols. As opposed to earlier assays, drug treated assays
were grown for 15 days as both the slow growth of
7C424 and reduced parasites numbers due to drug treat-
ment allowed for additional days before the culture
could no longer support the healthy growth of the ma-
jority parasite.
Quantification of parasite density
To determine the density of each parasite, allele specific
primers were used and compared to a standard curve
generated from known parasitaemias. D-soribtol (fluka)
synchronized parasites were used to create the standard
curve and DNA collected and extracted using an E.Z.N.
A. kit (Omega biotech). Parasitaemia of the culture was
determined using flow cytometry using previously
described methods [20]. The density of red blood cells
was determined using Flow count flourosphere (Beck-
man Coulter). Using the parasitaemia and red blood cell
density, the number of parasite genomes per microlitre
was calculated.
Allele specific primers were used to determine the
amount of each parasite in a mixed culture. The DNA
was analysed using a quantitative PCR assay based on a
shared TaqMan probe (Applied Biosystem). Primers
used for the Dd2 parasites are forward (AAT TGC CAA
AAC TAT TAA ATT TAA CAT TGA TAG) and reverse
(TGA ACA GAT TTC GTA GGA TCT TGT GA) with
a probe targeted towards a polymorphic sequence of the
gene msp1 (6 FAM ACT GAT CCA CTT GAA TTA
GMGBNFQ). These primers are also used to amplify
7C424 in drug treated assays as 7C424 inherited the
Dd2 allele of msp1. Primers used for HB3 are forward
(GAA ATT GCC AAA ACT ATT AAA TTT AAT ATT
GAT AG) and reverse (GGT TCA GTT GAT TCC TTT
GTT TCA AC) with the same probe used for Dd2.
Logarithmic standard curves were generated in triplicate
for each parasite used to ensure accurate quantitation
using 0.0 ηg/μL, 0.02 ηg/μL, 0.2 ηg/μL, 2.0 ηg/μL, 20
ηg/μL, and 200 ηg/μL. Primer specificity was determinedby generating additional standard curves with 200 ηg/μL
of competition parasite DNA added to each well
(Additional file 1).
Statistics
Statistics were performed using GraphPad Prizm 5.0. To
determine significant differences between parasites in
competition assay t-tests were performed on densities
determined on day 11 for Dd2 v HB3 assays and on day
15 for HB3 v 7C424 assays.
Results
Assay validation
To determine that the qPCR assay could accurately de-
tect parasite DNA over a wide range of concentrations
experiments were carried out to measure the amplifica-
tion of known quantities of DNA from each of the three
parasites used in competition assays (Dd2, HB3 and
7C424). The assay was able to accurately quantify DNA
over a 10,000 fold dynamic range (Additional file 1). In
addition, it was determined that DNA from a second
parasite clone had no significant impact on the ability to
quantify parasite DNA from the parasite of interest
(Additional file 1).
Dd2 competitively suppresses HB3
Pilot data obtained using relative quantification competi-
tion assays indicated that when Dd2 and HB3 were co-
cultured Dd2 eventually predominated. The growth dy-
namics were dissected in real time by monitoring co-
cultured Dd2 and HB3. Dd2 reached a significantly
greater density than HB3 (t-test, p= 0.0036) (Figure 1A).
Dd2 was analysed grown alone as a control and co-
cultured with HB3; the presence of HB3 in the mixed
culture had no effect on the growth of Dd2 (Figure 1B).
However significantly more HB3 was present when
grown alone than when co-cultured with Dd2 (t-test,
p< 0.0001), demonstrating that Dd2 competitively sup-
pressed HB3 (Figure 1C). The dynamics of HB3 growth
alone and in mixed culture differed greatly. In single cul-
ture, HB3 entered an exponential growth phase reaching
a maximum average density of 410,814 genomes per
microlitre. The maximum HB3 density in mixed culture
is 38,682 genomes per microlitre. Further investigation
focused on the investigation of the affects of drug treat-
ment on the dynamics of multi-clonal infections.
Drug treatment alters culture composition
To test for the affects of drug treatment on competition,
assays were carried out both in the presence and absence
of drugs. Because Dd2 competitively suppressed HB3 in
the absence of drugs, we also use a parasite combination
for which the CQS (HB3) parasite outgrew the CQR
(7C424) parasite in the absence of drugs. Pilot data
Figure 1 Infection dynamics of Dd2 and HB3. A) Dd2 (brown circles) competitively suppresses HB3 (black squares) when parasites are grown
together in culture. B) No difference is detected between Dd2 grown in single culture (orange circles) and in mixed culture with HB3 (brown
circles). C) HB3 reaches higher densities when grown in single culture (grey squares) than in mixed culture with Dd2 (black squares). Points are
means of three replicates, error bars represent standard deviation.
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the absence of drugs; subsequently, drug treated compe-
tition assays were carried out using the CQS clone HB3
and the CQR clone 7C424 to test the effect of drug
treatment on infections containing more than one para-
site. Control assays containing no drug demonstrated
that HB3 reached significantly higher densities than
7C424 (t-test, p< 0.0001) (Figure 2A). The density of
HB3 grown in single culture is not statistically different
from that grown in mixed culture (Figure 2B). However,
7C424 was suppressed by HB3, i.e. it was found at sig-
nificantly higher densities in single culture than in mixed
culture (t-test, p= 0.0047) (Figure 2C). Similar to results
between Dd2 and HB3, the maximum density reached
by 7C424 is reduced six-fold by the presence of HB3 in
culture.
Having established that the CQS parasite HB3 com-
petitively suppressed the CQR clone 7C424, the effect of
CQ on the dynamics of these two parasites grown to-
gether was determined. Parasites were cultured for 72
hours to establish an infection before constant CQ (50
nM) was initiated and maintained for the duration of the
assay. Fifty nM lies between the CQ IC50 values of HB3
and 7C424 (27.4 nM and 327.5 nM respectively) [19].
Application of drug treatment was delayed to mimic
conditions in a mouse model where competitive release
was observed when drug treatment was initiated after an
infection had been established [17]. Results of the drug
treated competition differed markedly from the no-drug
control as the resistant clone (7C424) expanded in num-
bers as the HB3 was cleared by CQ pressure which
resulted in a higher density of 7C424 than HB3 (t-test,
p= 0.0008) (Figure 2D). The application of drug not only
reversed the outcome of the competition (Figure 2A and
2D) but also resulted in a more pronounced difference
in densities between the two parasites. In the no-drug
treatment, HB3 was present at a seven-fold higher dens-
ity, and after drug treatment 7C424 was at 167-foldgreater density than HB3. The lower density of HB3 was
due to drug pressure and not competitive suppression
by 7C424, because HB3 grew similarly alone and in
mixed culture (Figure 2E). To determine if treatment-
induced facilitation occurred, a comparison was made
between the performance 7C424 with and without the
application of drugs. If competitive release occurred a
difference in parasite growth would be seen with and
without the application of drugs. No significant differ-
ence was detected between 7C424 grown alone and in
mixed culture; the addition of drug pressure effectively
removed the competitive suppression by HB3 and led to
the competitive release of 7C424, however, the extreme
release phenomenon of treatment-induced facilitation
(higher numbers in mixed culture than when grown
alone) was not observed (Figure 2F).
Timing of drug treatment affects growth relationships
To investigate the effect of dosing schedules on parasite
dynamics, drug pressure was initiated at a later time-
point. Parasites were allowed to grow for 120 hours be-
fore the initiation of drug treatment. The density of HB3
at the time of drug treatment (9,198 genomes per micro-
litre) in the later application is not statistically different
from the density at the time of early application (11,860
genomes per microlitre) of drug treatment. The later ap-
plication of drug allowed time for HB3 to competitively
suppress 7C424. The results observed after delayed ex-
posure to drug more closely resembled parasite growth
in no-drug controls, as HB3 significantly out-numbered
7C424 (t-test, p= 0.0069) (Figure 2G and Figure 3).
7C424 is suppressed by HB3 when drug pressure is
initiated later as evidenced by a higher density of 7C424
grown alone than when co-cultured with HB3 (t-test,
p= 0.0125) (Figure 2F). These results suggested that, at
least in an in vitro system, there is only a limited win-
dow of time in which drug resistant parasites can be
competitively released. The results of all drug treated
Figure 2 Infection dynamics of HB3 and 7C424. In the absence of drug pressure (A-C): A) HB3 (black squares) competitively suppresses 7C424
(blue diamonds). B) No difference is detected betweeHB3 grown in single culture (grey squares) and in mixed culture with 7C424 (closed black
squares). C) 7C424 reaches high densities single culture (light blue diamonds) than in mixed culture with HB3 (dark blue diamonds). When drug
pressure initiated 72 hours after the start of the assay (D-F): D) 7c424 (blue diamonds) experiences competitive release in a mixed infection with
HB3 (black squares) E) No difference is detected between HB3 grown in single culture (open grey squares) and in mixed culture with 7C424
(black squares): F) No difference is detected between 7C424 grown in single culture (open light blue diamonds) and in mixed culture with HB3
(dark blue diamonds). When drug pressure is initiated 120 hours after the start of the assay (G-I): G) 7c424 is competitively suppressed in a mixed
infection containing HB3 (black squares) and 7C424 (blue diamonds): H) No difference is detected between HB3 grown in single culture (grey
squares) and in mixed culture with 7C424 (black squares). I) 7C424 reaches greater densities when grown in single culture (light blue diamonds)
than in mixed culture with HB3 (dark blue diamonds). Initiation of drug pressure is indicated by a black arrow. Parasite densities are shown in
genomes per microlitre of culture. Points are means of three replicates, error bars represent standard deviation.
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work will focus on defining the boundaries for the tim-
ing of drug treatment that leads to competitive release.
Discussion
The impact of co-infection by more than one genetically
distinct Plasmodium parasite is an area of increasing
interest. Known sequence polymorphisms were used to
design allele specific primers to monitor the dynamics of
mixed cultures of clones Dd2 and HB3 along with the
effect of drug treatment. Dd2 competitively suppressed
HB3 in the absence of drug pressure. HB3 competitively
suppressed 7C424, a CQR clone, in the absence of drug
pressure, however, the application of drug pressure led
to competitive release when CQ was applied early butnot when drug was applied later. These data represent
the first attempt to use absolute quantification of com-
petitive suppression and the effects of drug treatment
over time in mixed P. falciparum infections in vitro.
This method provides a useful tool in the monitoring of
mixed infections and spread of drug resistant parasites.
It is of particular interest that competitive suppression is
asymmetrical: Dd2 competitive suppressed HB3, how-
ever, HB3 did not effect Dd2 growth. Asymmetrical
competition was also observed when HB3 was co-
cultured with the CQR clone 7C424 in the absence of
drug pressure. HB3 competitively suppressed 7C424;
however, the presence of 7C424 had no effect on HB3,
consistent with the observations of sensitive parasites
suppressing resistant parasites in the absence of drugs
Figure 3 Results of all drug treated assays. A) HB3 grown in single culture and B) mixed co-cultured with 7C424 in no-drug (black
triangles),72 hour drug treated (blue squares) and 120 hour drug treated competition assays (red circles). C) 7C424 grown in single culture and D)
co-cultured with HB3 in no- drug (black triangles), day 3 drug treated (blue squares) and day 5 drug treated competition assays (red circles).
Parasite densities are plotted in genomes per microlitre of culture. Points represent means of three replicates. Error bars represent standard
deviation.
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will determine if this dynamics is typical of all mixed
culture infections or if it varies by specific parasite
combinations.
Comparison of the growth of HB3 and 7C424, when
each was suppressed in mixed culture, demonstrated
that the shapes of the suppression growth curves were
markedly different than their growth curves when grown
alone. In fact, the maximum parasite density of HB3 and
7C424 was reduced in mixed culture 10-fold and six-
fold respectively. This is an intriguing result because dif-
ferences in parasite density between parasites grown
alone and in mixed culture would be expected to be
minimal without parasite interactions; however, in this
case it appears that the majority parasite may be inhibit-
ing the growth of the suppressed parasite. These interac-
tions could be as simple as interference competition,
wherein a particular clone is able to acquire necessary
resources faster; this could also entail a more complex
biology such as active competition, wherein one parasite
directly inhibits another, as has been reported for bacter-
ial systems [1].
Recently the idea that individual cells in a bacterial
population act as autonomous units has been replaced
by the hypothesis that social interactions are common inprokaryotic organisms [21]. This phenomenon, known
as quorum sensing, involves the accumulation of a signal
molecule leading to the activation of signal transduction
cascades that repress or activate target genes, bringing
about a change in collective behaviour [22]. Although
less well studied, evidence of quorum sensing has been
observed in eukaryotes [21] and in Plasmodium [23-25].
While the data presented here provide no direct evi-
dence for interference competition or quorum sensing,
the assay developed here is well suited to study a range
of possible interactions, including possible quorum
sensing.
Previous studies of mixed infections of human malaria
parasites have been somewhat restricted because they
determine only relative densities of parasites and be-
cause direct evidence of parasites interactions within a
human host are difficult to obtain due to ethical reasons.
The rodent malaria system allows for the investigation
of questions not easily answered using an in vivo P. fal-
ciparum system. One of the most important questions
that can be addressed by quantitative study of rodent
malaria is how the presence of more than one parasite
can affect the development and spread of drug resistant
parasites. It has been argued that when multi-clone
infections are common, within-host ecology can be the
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spreads [9]. Two of the most troubling observations con-
cerning the effect of drug treatment on mixed cultures
are the phenomena of competitive release and
treatment-induced facilitation. Wargo et al.[17] found in
a rodent model that when a mixed infection containing
a drug resistant and drug sensitive clone is treated with
drug, the removal of the sensitive parasite, which in the
absence of drug competitively suppresses the drug resist-
ant clone, leads to competitive release and allows for the
expansion of the drug resistant parasite. The increase in
drug resistant parasites is seen both in the asexual stages
circulating in the bloodstream and in the transmission
stages. Further studies found that the degree of competi-
tive release is dependent on the dose of drug given [18].
Treatment-induced facilitation also has been observed in
humans. A study on the effects of intermittent prevent-
ive treatment with sulphadoxine-pyrimethamine on
pregnant women in Malawi revealed that women who
had been subjected to recent drug treatment harboured
a less diverse parasite population, likely due to the elim-
ination of drug sensitive parasites by drug treatment [6].
Furthermore, women who had received recent drug
treatment were found to have a significantly higher para-
sitaemia and increased frequency of drug resistance phe-
notypes, an observation attributed to the competitive
facilitation of drug resistant parasites [6]. Potential
explanations exist to explain treatment-induced facilita-
tion [6,17]. One is resource competition, i.e. interference
competition, between parasites. In this case, removal of
the drug sensitive parasites will allow the resistant para-
sites access to resources that were previously unavail-
able. An alternative explanation is an immune-mediated
response: if the host immune system targets the majority
parasite within an infection, the removal of the majority
parasite (in this case the drug sensitive) by drug treat-
ment will cause the immune system to then target the
minority parasite. If a lag exists in immune retargeting
the minority parasite can take advantage and greatly ex-
pand in numbers.
Some insight into the mechanism leading to competi-
tive facilitation can be gained from the data in this study.
In a mixed infection that is drug treated 72 hours after
the initiation of the assay, the resistant parasite popula-
tion expands as the competitive suppression from the
sensitive clone is removed. Unlike previous results
[6,17], the density of the drug resistant parasite from the
mixed culture does not exceed the density of the resist-
ant parasite grown alone, indicating that the removal of
competitive suppression allows the initial release of the
resistant parasites. However, the lack of treatment-
induced facilitation in vitro, where resistant parasite
densities in mixed infection exceed that of single infec-
tions [17,18], does not rule out the role of an immunemediated host response. Additionally, it is possible that
the treatment-induced facilitation phenotype only exists
between specific combinations of parasites. Further stud-
ies using different combinations of parasites will reveal
whether the degree of competitive release observed is
genotype dependent. If genotypes are found to have an
impact on the magnitude of competitive release, it will
be possible to uncover underlying controlling genetic
factors. This study also demonstrated that changes in
the timing of the initiation of drug treatment had a dra-
matic effect on the outcome of the competition. When
CQ pressure was applied early, the competitive suppres-
sion of 7C424 by HB3 was removed and the drug resist-
ant parasite expanded to similar levels observed when
grown in single culture; however, when drug treatment
was started one cell cycle later, the results were dramat-
ically different. Even though the HB3 parasites were
eventually cleared from the culture, they remained able
to competitively suppress 7C424. A possible explanation
for the difference is a limiting supply of red blood cells;
most or all of the red blood cells suitable for parasite in-
vasion may have been used by the time HB3 was elimi-
nated from the culture by drug. If this is the case, 7C424
was therefore unable to expand due to the paucity of
available red blood cells, consistent with results observed
in P. chabaudi [26]. While the number of available red
blood cells was not determined following drug treatment
to eliminate HB3, such quantification will be possible in
future studies using this experimental system. An active
suppression mechanism may also be employed by HB3.
If this mechanism is similar to those observed in bac-
teria, a soluble factor in the culture could be indicated.
It is possible that a certain number of HB3 parasites
must be present for the soluble factor to surpass a
threshold density and for this effect to occur, but further
studies will be needed to investigate this possibility.
There has been an increased interest in applying math-
ematical models to predict the effects drug treatment
may have on multiple malaria infections. As an example
modeling was recently used to determine selection coef-
ficients in drug treated multiple infections of P. cha-
baudi [18]. Models can also offer some insight into the
types of interactions that take place within a multiple in-
fection [27]. However these models are reliant on high
quality measurement of parasite parameters to make ac-
curate predictions. The methods described here provide
an opportunity to quantify the growth of individual para-
sites both grown alone and within a multiple infection.
The timing and dosage of drug intervention and dos-
age has been shown to play a significant role in the out-
come of mixed infections [17,18]. The assay described
here will facilitate the investigation of the effects of vari-
ous drugs and doses on mixed cultures. If these assays
accurately mimic the conditions within a human host,
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implications for the malaria control policies to limit the
spread of drug resistant parasites.
Conclusions
Through the development of an absolute quantification
competition assay, it was determined that competitive
suppression is present when two genetically distinct P.
falciparum strains are co-cultured in vitro. Further, the
application of drug to a multiple infection containing
both drug sensitive and drug resistant parasites can lead
to the removal of competitive suppression, the competi-
tive release of and a greatly increased density of drug re-
sistant parasites. However, the timing of drug
application can have a great effect on parasite densities.
The tools developed here will enable experiments to dis-
sect interactions between multiple parasite clones in
in vitro infections with and without drug treatments.
This knowledge could inform novel control strategies to
contain the spread of drug resistant parasites.
Additional file
Additional file 1: Standard curves of all clones A) Dd2 DNA alone
(black circles) produces clear standard curve (R2 = 0.999) and adding
HB3 DNA (red squares) does not alter this curve (R2 = 0.998). B) HB3
DNA alone (black circles) produces a clear standard curve (R2 = 0.999) and
neither the addition of Dd2 DNA (red squares) nor 7C424 DNA (blue
diamonds) significantly alters the curve (R2 = 0.999, and 0.932
respectively). C) 7C424 DNA alone (blue diamonds) produces a clear
standard curve (R2 = 0.999) and adding HB3 DNA (black squares) does not
significantly alter the curve (R2= 0.997).
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